{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000017","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.943642+00:00","generated_at":"2026-06-27T17:41:43.579564+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xeris reaffirms 2021 net sales guidance at high-end $76-80M, 55% YoY growth","bullets":["Preliminary 2021 pro forma net sales expected at high-end of $76-80M guidance, ~55% growth vs 2020.","Year-end 2021 preliminary cash, equivalents, and investments ~$102M.","Over 20M Medicaid lives in IL, TN, PA, OH, CA now have unrestricted access to Gvoke as of Jan 1, 2022.","Third product Recorlev approved; launch in near term; additional $30M raised early 2022.","Full Q4 and FY 2021 results and 2022 guidance expected in March 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000017","json":"https://secwatch.observer/filing/0001867096-22-000017.json","markdown":"https://secwatch.observer/filing/0001867096-22-000017.md","text":"https://secwatch.observer/filing/0001867096-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/0001867096-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/xers-20220118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:41:43.579564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}